PAA:nanoalum |
|
Vaxjo ID |
394 |
|
Vaccine Adjuvant Name |
PAA:nanoalum |
|
Alternative Names |
it refers to aluminum oxyhydroxide nanoparticles stabilized with poly(acrylic acid). |
|
Adjuvant VO ID |
VO_0005676
|
|
Description |
PAA:nanoalum is a nanoparticle formulation derived from the clinical adjuvant Alhydrogel, modified to enhance its adjuvant activity and promote TH1 immune responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Polyactin A (PAA) has been used for the clinical treatment of impaired immunity in China for over 30years |
|
Structure |
The structure of PAA:nanoalum consists of aluminum oxyhydroxide nanoparticles stabilized by poly(acrylic acid) |
|
Appearance |
The appearance of PAA:nanoalum is typically as a stable suspension of nanoparticles |
|
Preparation |
PAA:nanoalum is prepared by dispersing Alhydrogel in the presence of poly(acrylic acid) and then processing it through high-pressure microfluidization. |
|
Function |
PAA:nanoalum represents a new class of alum adjuvant that preferentially enhances TH1 immunity to vaccine antigens. This adjuvant may be widely beneficial to vaccines for which TH1 immunity is important, including tuberculosis, pertussis, and malaria. |
|
Safety |
PAA:nanoalum has shown a favorable safety profile in preclinical studies, with reduced systemic toxicity compared to traditional aluminum adjuvants, but specific safety data in clinical trials are not provided. |
| References |
Orr et al., 2019: Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB. Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. NPJ vaccines. 2019; 4; 1. [PubMed: 30622742].
|
